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Pyrazolo[3,4-d]pyrimidinea b s t r a c t
An elegant solid-phase synthetic route of pyrazolo[3,4-d]pyrimidine derivatives via Aza-Wittig/electrocy-
clic ring closure reaction was developed and validated. By manipulating the R group from the primary
amine building block, one can easily prepare the library of pyrazolo[3,4-d]pyrimidine derivatives.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Solid-phase organic synthesis (SPOS) has played a crucial role in
modern drug discovery.1 It eliminates puriﬁcation of intermediates
that is required in solution-phase organic synthesis. Thus acceler-
ates the delivery of the target compounds. A wide variety of com-
pounds have been synthesized using SPOS in the past two decades
for hit seeking, lead identiﬁcation and optimization. Among them
heterocyclic compounds have attracted great interest to medicinal
chemists for many years due to their structural diversity, synthetic
versatility, desirable physicochemical properties, and important
pharmaceutical attributes.2,3 Pyrazolo[3,4-d]pyrimidine deriva-
tives are such a class of heterocyclic compounds whose biological
activities span a broad spectrum of antibacterial, antifungal, antivi-
ral, tuberculostatic, anti-inﬂammatory, and anticancer pharmacol-
ogies.4,5 Recent studies reported that pyrazolo[3,4-d]pyrimidine
derived Src kinase inhibitors were effective in cell cycle arrest
and tumor growth reduction in human medulloblastoma cells.6,7
Consequently, much chemistry effort was spent on the develop-
ment of facile and general synthetic methodologies to prepare
the pyrazolo[3,4-d]pyrimidine derivatives.8–13 Solid-phase organic
and combinatorial synthesis has played crucial roles in drug dis-
covery paradigm to explore uncharted chemical spaces as well as
to advance the lead compounds. As a part of our drug discovery
effort,14 we are particularly interested in the development of so-
lid-phase synthetic approaches to access diverse sets of heterocy-
clic compound libraries in a timely fashion. In this Letter, wereport our primary results of synthesizing the pyrazolo[3,4-
d]pyrimidine derivatives on a solid phase support. To the best of
our knowledge, this is the ﬁrst example in which tandem Aza-Wit-
tig/electrocyclic ring closure reaction was carried out on solid
phase.
Among various synthetic methodologies developed in the syn-
thesis of pyrazolo[3,4-d]pyrimidine template, the elegant Aza-Wit-
tig/electrocyclic ring closure approach is particularly attractive to
us.8,11,12 From the perspective of combinatorial synthesis, it is
highly desirable to introduce simultaneously four different R
groups to the fused ring systems as shown in Figure 1. If the
Aza-Wittig/electrocyclic ring closure transformation can be con-
ducted on solid-phase, the notorious triphenylphosphine oxide
waste from the Aza-Wittig reaction will be easily separated from
the product by a simple wash.
The synthesis started with precursor 1, which was prepared
using the modiﬁed literature procedure;11 it was ﬁrst hydrolyzed
by sodium hydroxide to provide carboxylic acid 2. Intermediate 2
was easily loaded on Rink resin (0.47 mmol/g) using the conven-
tional coupling method with DIC and HOBt to form intermediate
3. The resin was then treated with various primary amines in the
presence of trimethyl formate to form imine 4. Imine 4was further
treated with triphenylphosphine in dichloromethane overnight,
which gave aza-ylide 5. Compound 5 was then treated with isocy-
anate in dichloromethane, and the resin immediately turned deep
red in color. After shaking for 2 h the resin was washed with
dichloromethane, methanol, and dried in vaccuo. The dried resin
was then treated twice with 20% TFA solution for 15 min. Then
Figure 1. Aza-Wittig/electrocyclic ring closure synthetic approach.
Table 1
The product yield and purity from solid phase synthesis in Figure 1
Entry Compound 7a R0 R00 Purityb (%) Yieldc (%)
1 7a Me cHexyl 5 7.0
2 7b Me 4-BrPh 100 60
3 7c t-Bu 4-BrPh 88 36
4 7d Bn n-Bu 23 15
5 7e Ph 4-BrPh 100 67
6 7f 4-ClPh Et 100 9.6
7 7g 4-MeOPh 4-NO2Ph 90 76
8 7h 4-CNPh 4-MeSPh 0 0
a 20% TFA solution contains 79% dichloromethane, 20% triﬂuoroacetic acid, and
1% triisopropylsilane.
b The crude product’s purity was determined by HPLC.
c Yield was calculated from the ﬁnal product puriﬁed by Gilson LC system.
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bined ﬁltrate was concentrated under reduced pressure. The resid-
ual crude product was analyzed with LC–MS and puriﬁed by HPLC.
The results are summarized in Table 1.
As shown in the synthetic scheme (Fig. 2), R0 was introduced
from primary amine R0NH2 by forming a Schiff base in imine 4,
while R00 was introduced from isocyanate R00NCO via Aza-Wittig/
electrocyclic ring closure reaction. In order to explore the general-
ity of this solid-phase synthetic route to pyrazolo[3,4-d]pyrimidineFigure 2. Solid phase synthetic scheme ofderivatives, we purposely selected a diverse set of the primary
amines and the isocyanates in our chemistry demonstration.
Based on the results listed in Table 1, eight compounds can be
classiﬁed into three groups: the ﬁrst group consists of 7b, 7e,
and 7g, which were obtained in 60%, 67% and 75% yields respec-
tively; the second group consists of 7a, 7d, and 7f, which were pro-
duced in 7%, 15%, and 9.6% yields respectively; the third group
consists of compound 7h, which was not obtained. This is likely
due to the poor nucleophilicity of the 4-cyanoaniline, which pre-
cluded the formation of the corresponding Schiff base 4 at step 3,
leading to the synthetic failure of 7h. Similarly, the poor nucleophi-
licity of the 4-chloroaniline could explain the low yield of product
7f. Products 7a, 7d, and 7f contain alkyl groups that were derived
from alkyl isocyanates. Their low yield could be attributed to the
poor stability of the alkyl isocyanates which were sensitive to
moisture and could degrade easily during storage. Based on these
observations, in the production of the pyrazolo[3,4-d]pyrimidine
library, it is very important to select the more nucleophilic amines
as the building blocks and ensure that the isocyanates were kept in
anhydrous conditions.
In the experiment to evaluate how the TFA concentration may
affect the resin cleavage, it was interesting to discover that high
concentration of TFA could break the conjugation system, causing
removal of R’ group to produce compound 8 as shown in Figure 3.pyrazolo[3,4-d]pyrimidine derivatives.
Figure 3. The chemistry scheme in 95% TFA cleavage.
Table 2
Product distribution under 95% TFA cleavage condition in Figure 2
R0 in compound 6 & 7a Purityb (%) Yieldc (%) Compound 7/compound
8d
Me 93 60 62/38
t-Butyl 82 36 20/80
Phenyl 97 25 93/7
2,4-Dimethoxybenzyl 70 60 0/100
a Cleavage condition: the resin was treated with 95% TFA solution for 1 h, and
then ﬁltered; the resin was washed with dichloromethane (3  3 mL for 15 min);
95% TFA solution contains 1% tributylsilane and 4% dichloromethane.
b Crude product’s purity was determined by HPLC.
c Combined yield of compounds 7 and 8 after puriﬁed by Gilson LC system.
d The ratio was determined from the crude product mixture by HPLC.
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product distribution of compounds 7 and 8, three analogues were
treated with 95% TFA for one hour. As shown in Table 2, when R’
was the methyl group, the crude product contained 62% compound
7 and 38% compound 8; when R’ was t-butyl, the crude product
contained 80% compound 8 and 20% compound 7; when R’ was
the phenyl group, the crude product contained only 7% compound
8 and 93% compound 7, indicating the phenyl group was quite
stable under such an acidic condition. When R’ was 2,4-dimethoxy-
benzyl, a very acid-sensitive functional group, 100% compound 8
was obtained. Therefore, by using different R’ group and
controlling TFA concentration, we could easily access a new pyraz-
olo[3,4-d]pyrimidine derivative library.
In summary, an elegant solid-phase synthetic route of pyrazol-
o[3,4-d]pyrimidine derivatives was developed and validated. Bymanipulating the R group from the primary amine building block,
one can easily transform the pyrazolo[3,4-d]pyrimidine library into
a new collection of compounds. The large scale production of the
new library using this solid-phase synthesis method is currently
underway and the results will be reported soon.
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